Aditya Sivakumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aditya Sivakumar has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Ajit S. Divakaruni
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, USA
1 shared publicationAlexandra C. Turmon
Department of Biological Chemistry, David Geffen School of Medicine, UCLA, Los Angeles, USA
1 shared publication- Alexey Nesvizhskii
Department of Pathology, University of Michigan, Ann Arbor, MI, USA
1 shared publication - Andrea B. Ball
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA
1 shared publication - Chau Ngo
Department of Biological Chemistry, David Geffen School of Medicine, UCLA, Los Angeles, USA
1 shared publication - Elijah Biletch
Biological Chemistry Department, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by Springer Nature in Nature Chemistry
- p. 1-12
Small-molecule binding-site discovery using silyl ether-enabled chemoproteomics
For chemical probe and drug discovery campaigns, the pairing of mass spectrometry-based chemoproteomics with photoaffinity labelling has emerged as a favoured approach for target discovery and mode of action assignment. However, photocrosslinked peptide-compound adducts raise analytic challenges for quantitative binding site discovery. Here, to address these challenges, we establish the Silyl Ether Enables Chemoproteomic Interaction and Target Engagement (SEE-CITE) method. SEE-CITE incorporates a fully functionalized chemically cleavable photocrosslinking handle that enables precise site-of-labelling identification and head-to-head comparisons of relative binding site engagement by chemically diverse compounds. To ensure high-confidence localization of labelled residues, we extended the MSFragger algorithm of the FragPipe computational platform to report localization scores customized for photoaffinity labelling and SEE-CITE data. When applied to scout fragments and analogues of select FDA-approved kinase inhibitors, SEE-CITE delineates known drug binding sites and uncovers small-molecule binding sites that affect the protein activity of RTN4 and COX5A.
- 27 April 2026
- Published by Springer Nature in Nature Chemistry
- p. 1-12
Open AccessSmall-molecule binding-site discovery using silyl ether-enabled chemoproteomics
For chemical probe and drug discovery campaigns, the pairing of mass spectrometry-based chemoproteomics with photoaffinity labelling has emerged as a favoured approach for target discovery and mode of action assignment. However, photocrosslinked peptide-compound adducts raise analytic challenges for quantitative binding site discovery. Here, to address these challenges, we establish the Silyl Ether Enables Chemoproteomic Interaction and Target Engagement (SEE-CITE) method. SEE-CITE incorporates a fully functionalized chemically cleavable photocrosslinking handle that enables precise site-of-labelling identification and head-to-head comparisons of relative binding site engagement by chemically diverse compounds. To ensure high-confidence localization of labelled residues, we extended the MSFragger algorithm of the FragPipe computational platform to report localization scores customized for photoaffinity labelling and SEE-CITE data. When applied to scout fragments and analogues of select FDA-approved kinase inhibitors, SEE-CITE delineates known drug binding sites and uncovers small-molecule binding sites that affect the protein activity of RTN4 and COX5A.